ImageneBio (NASDAQ:IMA) Shares Down 1% – Time to Sell?

Shares of ImageneBio, Inc. (NASDAQ:IMA) dropped 1% on Monday. The stock traded as low as $3.99 and last traded at $4.00. 6,063 shares were traded during mid-day trading, a decline of 51% from the average daily volume of 12,346 shares. The stock had previously closed at $4.04.

Analyst Ratings Changes

A number of brokerages have recently weighed in on IMA. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImageneBio in a report on Friday, September 25th. HC Wainwright initiated coverage on shares of ImageneBio in a report on Friday, August 21st. They issued a “buy” rating and a $28.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, ImageneBio currently has a consensus rating of “Hold” and an average target price of $29.00.

ImageneBio Trading Down 0.7%

The business’s fifty day moving average price is $4.92 and its two-hundred day moving average price is $5.41. The firm has a market cap of $46.55 million, a P/E ratio of -0.90 and a beta of 0.74.

ImageneBio (NASDAQ:IMA) last announced its earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.27. Research analysts predict that ImageneBio, Inc. will post -3.23 EPS for the current fiscal year.

Institutional Investors Weigh In On ImageneBio

Several institutional investors and hedge funds have recently bought and sold shares of IMA. Stonepine Capital Management LLC bought a new stake in shares of ImageneBio in the 2nd quarter valued at approximately $539,044,000. Trails Edge Capital Partners LP bought a new position in ImageneBio in the second quarter valued at approximately $1,663,824. Hsbc Holdings PLC bought a new stake in shares of ImageneBio in the 2nd quarter valued at about $208,000. Cable Car Capital LP bought a new stake in shares of ImageneBio in the 2nd quarter valued at $4,611,000. Finally, Blue Owl Capital Holdings LP bought a new stake in shares of ImageneBio during the second quarter worth $5,414,000. Institutional investors own 75.00% of the company’s stock.

About ImageneBio

ImageneBio, Inc is a biotechnology company focused on developing molecular diagnostic technologies for precision oncology. The company aims to generate actionable information about cancer biology from blood-based samples, supporting more informed treatment decisions and disease monitoring.

ImageneBio’s platform is designed to analyze tumor-derived molecular signals and may support applications such as cancer detection, treatment selection, and monitoring of treatment response or disease progression.